

# The change in glycaemic control immediately after COVID-19 vaccination in people with type 1 diabetes

Since the first weeks of the COVID-19 vaccination programme in the UK and elsewhere, there have been reports from patients with insulin-treated diabetes of changes in blood glucose profile in the days after the vaccination. In a study published in December 2021 in the journal *Diabetic Medicine* (Heald et al, 2021), we have validated this observation, which has also been noted by many clinicians over the last 12 months.

Facilitated by flash glucose monitoring technology (Pickup et al, 2011), the team examined the interstitial glucose profile of 97 consecutive adults with type 1 diabetes in the periods immediately before and after their first COVID-19 vaccination. The primary outcome measures were the percentage of interstitial glucose readings within the target range of 3.9–10 mmol/L (time in range; TIR) in the 7 days prior to the vaccination and 7 days after the vaccination.

Overall, 58% of participants showed a reduction in TIR the week after COVID-19 vaccination. Importantly, one in three individuals had a >10% reduction in TIR, and one in ten showed a decrease of >20%. The mean change in TIR in the week following vaccination was most pronounced for people taking metformin or dapagliflozin in addition to a basal-bolus insulin regimen (change in TIR, -7.6%) and for those below the median HbA<sub>1c</sub> of 56 mmol/mol (7.6%) pre-vaccination (change in TIR, -5.7%).

One possible mechanism for the temporary change in blood glucose profile described here is stimulation of the immune system, resulting in a transient stress response, to a milder degree than would typically occur with a COVID-19 infection. Such physiological stress has the potential to increase counter-regulatory hormone levels for some days and has been noted previously (Mifsud et al, 2018).

The authors suggest that further investigation in a larger, multi-site patient series would be helpful in elucidating this phenomenon further. Individual patient knowledge and engagement remain cornerstones of diabetes management. The results here raise the question of whether people with type 1 diabetes should be given specific advice in advance of any further COVID-19 vaccinations, including the current booster programme, regarding potential temporary effects on their blood glucose control. ■

Heald AH, Stedman M, Horne L et al (2021) The change in glycaemic control immediately after COVID-19 vaccination in people with type 1 diabetes. *Diabet Med* 22 Dec: e14774 [Epub ahead of print]

Mifsud S, Schembri EL, Gruppeta M (2018) Stress-induced hyperglycaemia. *Br J Hosp Med (Lond)* 79: 634–9

Pickup JC, Freeman SC, Sutton AJ (2011) Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. *BMJ* 343: d3805

Adrian Heald  
Salford Royal NHS Foundation  
Trust and University  
of Manchester

Linda Horne  
Vernova Healthcare,  
Macclesfield

Simon G Anderson  
School of Medicine and  
Manchester Academic Health  
Sciences Centre, University  
of Manchester

J Martin Gibson  
Salford Royal NHS Foundation  
Trust and University  
of Manchester

Received 2 June 2021 | Accepted 20 December 2021  
DOI: 10.1111/dm.14774

RESEARCH ARTICLE

**The change in glycaemic control immediately after COVID-19 vaccination in people with type 1 diabetes**

Adrian H. Heald<sup>1,2</sup> | Michael Stedman<sup>3</sup> | Linda Horne<sup>4</sup> | Rustam Rea<sup>5</sup> | Martin Whyte<sup>6</sup> | J. Martin Gibson<sup>1,2</sup> | Simon G. Anderson<sup>1,8</sup> | William Ollier<sup>7</sup>

<sup>1</sup>School of Medicine, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK  
<sup>2</sup>Department of Diabetes and Endocrinology, Salford Royal Hospital, Salford, UK  
<sup>3</sup>Yas Consortium, Andover, UK  
<sup>4</sup>Vernova Healthcare, Watersop, Medical Centre, Macclesfield, UK  
<sup>5</sup>Oxford Centre for Diabetes, Endocrinology and Metabolism and NIDDK Oxford Biomedical Research Centre, Oxford University Hospitals NHS FT, Oxford, UK  
<sup>6</sup>Department of Clinical & Experimental Medicine, University of Surrey, Guildford, UK  
<sup>7</sup>University of the West Indies, Cavehill Campus, Bridgetown, Barbados  
<sup>8</sup>Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK  
<sup>9</sup>Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK

**Correspondence**  
A.H. Heald, Salford Royal Hospital, Stott Lane, Salford, M6 8BU  
Email: adrian.heald@manchester.ac.uk

**Funding information**  
There was no external funding for this study.

**Abstract**  
**Aims:** Evidence suggests that some people with type 1 diabetes mellitus (T1DM) experience temporary instability of blood glucose (BG) levels after COVID-19 vaccination. We aimed to assess this objectively.  
**Methods:** We examined the interstitial glucose profile of 97 consecutive adults (age ≥ 18 years) with T1DM using the FreeStyle Libre<sup>®</sup> flash glucose monitor in the periods immediately before and after their first COVID-19 vaccination. The primary outcome measure was percentage (%) interstitial glucose readings within the target range 3.9–10 mmol/L for 7 days prior to the vaccination and the 7 days after the vaccination. Data are mean ± standard error.  
**Results:** There was a significant decrease in the % interstitial glucose on target (3.9–10.0) for the 7 days following vaccination (mean 52.2% ± 2.0%) versus pre-COVID-19 vaccination (mean 55.0% ± 2.0%) ( $p = 0.009$ ). 38% of individuals with T1DM showed a reduction in the 'time in target range' in the week after vaccination; 30% showed a decrease of time within the target range of over 10%, and 10% showed a decrease in time within target range of over 20%. The change in interstitial glucose proportion on target in the week following vaccination was most pronounced for people taking metformin/dapagliflozin + basal bolus insulin (change: -7.6%) and for people with HbA<sub>1c</sub> below the median (change: -5.7%).  
**Conclusion:** In T1DM, we have shown that initial COVID-19 vaccination can cause temporary perturbation of interstitial glucose, with this effect more pronounced in people taking oral hypoglycaemic medication plus insulin, and when HbA<sub>1c</sub> is lower.

**KEYWORDS**  
COVID-19 vaccination, flash glucose monitoring, glycaemic stability, HbA<sub>1c</sub>, type 1 diabetes

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  
© 2021 The Authors. *Diabetic Medicine* published by John Wiley & Sons Ltd on behalf of Diabetes UK.  
*Diabetic Medicine* 2021; 34(12): 1474–1474  
<https://doi.org/10.1111/dm.14774>

[Click here to read the study in full](#)

**Citation:** Heald A, Horne L, Anderson SG, Gibson JM (2022) The change in glycaemic control immediately after COVID-19 vaccination in people with type 1 diabetes. *Journal of Diabetes Nursing* 26: [Early view publication]